Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00612664 · ClinicalTrials.gov registry record · Phase 2
Phase II, 2nd Line Melanoma - RAND Monotherapy
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 158
- Enrollment target
NCT00612664 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 158 participants.
The verdict
NCT00612664, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 158 participants
- Enrollment target
Study Summary
The main purpose of this study is to estimate the proportion of patients with a type of skin cancer called melanoma who are progression free, (that is, the cancer has not gotten substantially worse), when treated with Anti-CD137 (4-1BB) (BMS-663513) at 0.1 mg/kg, 1 mg/kg or 5 mg/kg every 3 weeks or 1 mg/kg every 6 weeks
Interventions
- DRUG Anti-CD137 (4-1BB) (BMS-663513)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00612664
The ClinicalTrials.gov registry entry for NCT00612664 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anti-CD137 (4-1BB) (BMS-663513) is the first listed.
NCT00612664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00612664 about?
NCT00612664 is a clinical study titled "Phase II, 2nd Line Melanoma - RAND Monotherapy". The main purpose of this study is to estimate the proportion of patients with a type of skin cancer called melanoma who are progression free, (that is, the cancer has not gotten substantially worse), when treated with Anti-CD137 (4-1BB) (BMS-663513) at 0.1 mg/kg, 1 mg/kg or 5 mg/kg every 3 weeks or ...
What is the current status of trial NCT00612664?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 158 participants. The study started on 2008-03. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00612664?
The interventions under investigation include: Anti-CD137 (4-1BB) (BMS-663513) (DRUG).
Who is sponsoring clinical trial NCT00612664?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.